Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-07
2011-06-07
Shafer, Shulamith H (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C530S324000, C530S300000
Reexamination Certificate
active
07956038
ABSTRACT:
The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of GASP1 for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5639638 (1997-06-01), Wozney et al.
patent: 5700911 (1997-12-01), Wozney et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5756457 (1998-05-01), Wang et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5914234 (1999-06-01), Lee et al.
patent: 5942420 (1999-08-01), Holtzman
patent: 5994618 (1999-11-01), Lee et al.
patent: 6004937 (1999-12-01), Wood et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6340668 (2002-01-01), Celeste et al.
patent: 6368597 (2002-04-01), Strassmann et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6372454 (2002-04-01), Duan et al.
patent: 6437111 (2002-08-01), Wozney et al.
patent: 6537966 (2003-03-01), Duan et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 2002/0004224 (2002-01-01), Sheppard
patent: 2002/0127234 (2002-09-01), El Halawani et al.
patent: 2002/0150577 (2002-10-01), Lee et al.
patent: 2003/0104406 (2003-06-01), Wolfman et al.
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2003/0162714 (2003-08-01), Hill et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0077053 (2004-04-01), Lee et al.
patent: 2004/0138118 (2004-07-01), Wolfman et al.
patent: 2004/0142382 (2004-07-01), Veldman et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0043232 (2005-02-01), Lee et al.
patent: 1 061 940 (2003-12-01), None
patent: 1 444 985 (2004-08-01), None
patent: WO 94/21681 (1994-09-01), None
patent: WO 94-26892 (1994-11-01), None
patent: WO 96-01845 (1996-01-01), None
patent: WO 98/33887 (1998-08-01), None
patent: WO 98/35019 (1998-08-01), None
patent: WO 99/24058 (1999-05-01), None
patent: WO 99/45949 (1999-09-01), None
patent: WO 99/56768 (1999-11-01), None
patent: WO 00/11163 (2000-03-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 01/64888 (2001-07-01), None
patent: WO 02/09641 (2002-02-01), None
patent: WO 02/068650 (2002-09-01), None
patent: WO 03/027248 (2003-04-01), None
patent: WO 04-058988 (2004-07-01), None
Costelli et al. 2008. Eur J Clin Invest 38 (7): 531-538.
Tobin et al 2005. Current Opinion in Pharm. 5:328-332.
Bradley et al. 2008. Cell. Mol Sci. 65:2119-2124.
Dominique et al 2006. Exp Cell Res. 312:2401-2414.
Schara et al 2006. Seminars in Ped Neurology 12:71-79.
Vernino 2007. Neurotherapeutics 4:305-314.
Hansen et al. 2006. Pharmacology & Therapeutics 109 :162-172.
Jurkat-Rott et al. 2006. J. Neurol. 2006. 253:1391-1398.
International Search Report in PCT/US02/30452 dated Feb. 4, 2003.
International Search Report in PCT/US02/03467 dated Feb. 25, 2003.
International Search Report in PCT/US03/05151 dated Aug. 24, 2006.
International Search Report in PCT/US03/05150 dated Oct. 20, 2006.
Alexander et al., “Human Parathyroid Hormone 1-34 Reverses Bone Loss in Ovariectomized Mice,”J. Bone Miner. Res. 16:1665-1673 (2001).
Alliel et al., “Testican, a Multidomain Testicular Proteoglycan Resembling Modulators of Cell Social Behaviour,”Eur. J. Biochem. 214:347-350 (1993).
Amthor et al., “The Expression and Regulation of Follistatin and a Follistatin-like Gene During Avian Somite Compartmentalization and Myogenesis,”Dev. Biol. 178:343-362 (1996).
Andersson et al., “Repeated In Vivo Determinations of Bone Mineral Density During Parathyroid Hormone Treatment in Ovariectomized Mice,”J. Endocrinol. 170:529-537 (2001).
Ashmore et al., “Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and ‘Double-Muscled’ Cattle,”Growth38:501-506 (1974).
Attisano et al., “Activation of Signalling by the Activin Receptor Complex,”Mol. Cell. Biol. 16:1066-1073 (1996).
Bakker et al., Duchenne and Becker Muscular Dystrophies. InDiagnostic Criteria for Neuromuscular Disorders, 2nd ed., Emery, ed., Royal Society of Medicine Press, 1998; pp. 1-4.
Bartholin et al., “FLRG, an Activin-Binding Protein, is a New Target of TGFβ Transcription Activation Through Smad Proteins,”Oncogene20:5409-5419 (2001).
Bogdanovich et al., “Functional Improvement of Dystrophic Muscle by Myostatin Blockade,”Nature420:418-421 (2002).
Bowie et al. “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science247:1306-1310 (1990).
Brown et al., “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-Beta's 1, 2, and 3,”Growth Factors3:35-43 (1990).
Bulfield et al., “X Chromosome-Linked Muscular Dystrophy (mdx) in the Mouse,”Proc. Natl. Acad. Sci. U.S.A. 81:1189-1192 (1984).
D'Angelo et al., “Authentic Matrix Vesicles Contain Active Metalloproteases (MMP),”J. Biol. Chem. 276:11347-11353 (2001).
Derynck et al., “Human Transforming Growth Factor-β Complementary DNA Sequence and Expression in Normal and Transformed Cells,”Nature316:701-705 (1985).
Donoghue et al., “Rostrocaudal Gradient of Transgene Expression in Adult Skeletal Muscle,”Proc. Natl. Acad. Sci. U.S.A. 88:5847-5851 (1991).
Emery, “The Muscular Dystrophies,”Lancet359:687-695 (2002).
Escolar et al., “Pharmacologic and Genetic Therapy for Childhood Muscular Dystrophies,”Current Neurology and Neuroscience Reports1:168-174 (2001).
Federman et al., “Binding of GDF-8 to the activin type IIB receptor is blocked by the GDF-8 Propeptide and enhanced by the activin binding protein, follistatin,”Journal of Bone and Mineral Research15(supp. 1):S463 (2000).
Gamer et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos,”Dev. Biol. 208:222-232 (1999).
Gamer et al., “Gdf11 is a Negative Regulator of Chondrogenesis and Myogenesis in the Developing Chick Limb,”Dev. Biol. 229:407-420 (2001).
Gentry et al., “The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor,”Biochemistry29:6851-6857 (1990).
Gillis, “Multivariate Evaluation of the Functional Recovery Obtained by the Overexpression of Utrophin in Skeletal Muscles of themdxMouse,”Neuromuscular Disorders12:S90-S94 (2002).
Girard et al., “Modulation of Endothelial Cell Adhesion by Hevin, an Acidic Protein Associated with High Endothelial Venules,”J. Biol. Chem. 271:4511-4517 (1996).
Gonzalez-Cadavid et al., “Organization of the Human Myostatin Gene and Expression in Healthy Men and HIV-Infected Men With Muscle Wasting,”Proc. Natl. Acad. Sci. U.S.A., 95:14938-14943 (1998).
Gosselink et al., “Respiratory muscle involvement in multiple sclerosis”Eur Respir J13:449-454 (1999).
Grady et al:, “Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy,”Cell90:729-738 (1997).
Granchelli et al., “Pre-Clinical Screening of Drugs Using themdxMouse,”Neuromuscular Disorders10:235-239 (2000).
Hamrick et al., “Femoral Morphology and Cross-Sectional Geometry of Adult Myostatin-Deficient Mice,”Bone27:343-349 (2000).
Hamrick et al., “Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice”Calcified Tissue Inter
Hill Jennifer J.
Wolfman Neil M.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Shafer Shulamith H
Wyeth LLC
LandOfFree
GASP1: a follistatin domain containing protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with GASP1: a follistatin domain containing protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GASP1: a follistatin domain containing protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2744526